NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin.
Theranostics. 2021 Feb 25;11(9):4381-4402. doi: 10.7150/thno.53652. eCollection 2021.
Theranostics. 2021.
PMID: 33754067
Free PMC article.